Treating urothelial transitional cell cancer (TCC) with methotrexate (M), carboplatin (C), novantrone (N) and Vincristine (O)
- 作者：Athanassiou ; A.E. ; Pectasidis ; D. ; Antoniou ; F. ; Varthalitis ; I. ; Dimitriadis ; M. ; Tsintavis ; A. ; et. al.
- 刊名：European Journal of Cancer
- 出版年：1995
- 期刊代码：88_09598049
- 类别：med
- 出版时间：November, 1995
- 卷：31
- 期：Supplement 6
- 页码：S242
- 文件大小：132 K
摘要
Cisplatin combination chemotherapy (CT) is considered as standard therapy for TCC and MVAC as the mostly tested regime in this condition. The aim of this study was to test efficacy and toxicity of a combination by substituting the drugs of MVAC (except for M that was given in increased dose) by their analogues (MCNO) in pts with TCC. We administered M 300 mg/m2 as a 4 h infusion (with fol.acid rescue), C 300 mg/m2, N 12 mg/m2 and O 1 mg/m2, all given on d. 1, q 3w. 47 consecutive and CT-naive pts aged 65 y. (43-74) received MCNO as follows: 16 pts as postsurgical adjuvant CT with 10 NED for 6+ (4-16+) mos, 5 relapsed/dead and 1 relapsed/alive on CT. 20 pts as neoadjuvant CT with 3 cCR (0 pCR), 7 cPR and 10 SD. 9 pts were operated (0 pCR/8 sCR), 5 of them are NED for 5+ (2-28+) mos, 6 survive on CT and 9 died. And 11 pts with metastatic disease and with 2 cCR/NED for 9+ and 23+ mos, 1 cPR, 4 SD and 4 PD. Alive off CT 2, alive on CT 3, dead 6. Toxicity gr. > 2: Hb 21 (45%) pts, ANC 32 (68%), thrombocytopenia 20 (43%), G.I 14 (30%) with no toxic death. Our conclusion is that MCNO does not differ from other similar regimes in terms of efficacy/toxicity.